Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Barbora, Pipek"'
Autor:
Michal Stepan, Premysl Falt, Barbora Pipek, Petr Fojtik, Martin Hanousek, Martin Hill, Ondrej Urban
Publikováno v:
Biomedical Papers, Vol 167, Iss 1, Pp 69-73 (2023)
Aims. Sufficient visibility of the mucosa during upper endoscopy is crucial for successful diagnosis, especially for early neoplastic lesions. Data documenting the effect of administration of mucolytic solution prior to gastroscopy in order to improv
Externí odkaz:
https://doaj.org/article/3c027d46433645e1beb80cafebacff6f
Autor:
Katarina Mitrova, Barbora Pipek, Martin Bortlik, Ludek Bouchner, Jan Brezina, Tomas Douda, Tomas Drasar, Pavel Drastich, Premysl Falt, Pavel Klvana, Vaclav Leksa, Ales Novotny, Pavel Svoboda, Jan Skorpik, Jan Ulbrych, Marek Veinfurt, Blanka Zborilova, Milan Lukas, Dana Duricova
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Vedolizumab demonstrated different placental pharmacokinetics than other immunoglobulin G1 antibodies, leading to lower drug levels in cord blood in contrast to maternal blood at the time of delivery. The placental transfer of ustekinumab
Externí odkaz:
https://doaj.org/article/66e3c88cc9384a3790d80746cc08cc2d
Autor:
Katarina, Mitrova, Barbora, Pipek, Martin, Bortlik, Ludek, Bouchner, Jan, Brezina, Tomas, Douda, Tomas, Drasar, Pavel, Klvana, Pavel, Kohout, Vaclav, Leksa, Petra, Minarikova, Ales, Novotny, Pavel, Svoboda, Jan, Skorpik, Jan, Ulbrych, Marek, Veinfurt, Blanka, Zborilova, Milan, Lukas, Dana, Duricova
Publikováno v:
Journal of Crohn's and Colitis. 16:1808-1815
Background and Aims Evidence on the safety of newer biologics during pregnancy is limited. We aimed to assess the safety of ustekinumab and vedolizumab treatment during gestation on pregnancy and infant outcome. Furthermore, we evaluated the placenta
Autor:
Barbora Pipek, Dana Ďuricová, Katarína Mitrová, Martin Bortlík, Luděk Bouchner, Jan Březina, Tomáš Douda, Tomáš Drašar, Pavel Drastich, Přemysl Falt, Pavel Klvaňa, Pavel Kohout, Václav Leksa, Aleš Novotný, Pavel Svoboda, Jan Škorpík, Jan Ulbrych, Marek Veinfurt, Blanka Zbořilová, Milan Lukáš
Publikováno v:
Gastroenterologie a hepatologie. 76:46-54
Background: Inflammatory bowel disease (IBD) is mostly diagnosed in young women of fertile age, and a significant number of patients become pregnant while they have the disease. The remission of the illness, which is often achieved by intensive anti
Autor:
Martin Bortlík, Dana Ďuricová, Luděk Hrdlička, Petra Matějková, Aleš Novotný, Pavel Drastich, Václav Mandys, Petra Mináriková, Barbora Pipek, Ivana Kajzrlíková, Lenka Nedbalová, Jana Koželuhová, Naděžda Machková, Vladimír Zbořil, Lucie Prokopová, Pavel Kohout, Zuzana Šerclová, Martin Vašátko, Tomáš Douda, Jiří Stehlík, Karel Mareš, Milan Lukáš
Publikováno v:
Gastroenterologie a hepatologie. 76:13-28
Publikováno v:
Gastroenterologie a hepatologie. 75:345-349
The CDED diet (Crohn‘s disease exclusion diet) is the first elimination diet that induces and maintains remission in adult patients with mild to moderate Crohn‘s disease. It is based on mandatory, recommended and prohibited foods. In our article
Publikováno v:
Casopis lekaru ceskych. 161(3-4)
Clostridioides difficile (Clostridium difficile in older taxonomy) is a gram-positive anaerobic and bacteria enabled by endospores. Clostridioides difficile is currently the main cause of nosocomial infections in developed countries. Due to the high
Publikováno v:
Vnitřní lékařství. 67:109-113
Crohnova choroba (CN) a ulcerozni kolitida (UC) patři do skupiny onemocněni s nazvem idiopaticke střevni zaněty (IB - inflammatory bowel disease). IBD maji dosud ne zcela jasnou etiologii, bývaji diagnostikovany převažně v mladsim věku a v p
Autor:
Barbora Pipek
Publikováno v:
Gastroenterologie a hepatologie. 74:558-561
Autor:
Barbora Pipek
Publikováno v:
Klinická farmakologie a farmacie. 34:74-77
Idiopaticke střevni zaněty (IBD‑inflammatory bowel disease) jsou skupinou onemocněni, ktere zahrnuji Crohnovu chorobu (CN) a ulcerozni kolitidu (UC) a postihuji předevsim mlade dospěle v produktivnim věku. Anti‑TNF latky představuji prvni